

Daftar Pustaka

1. WHO | Cardiovascular diseases (CVDs). World Health Organization; [cited 2016 Jan 21]; Available from:
<http://www.who.int/mediacentre/factsheets/fs317/en/#.VrIw5CcYeDI.mendeleey>
2. Balitbang Kemenkes RI. Riset Kesehatan Dasar 2013 [Internet]. Riset Kesehatan Dasar. Jakarta; 2013. Available from:
[http://www.depkes.go.id/resources/download/general/Hasil Riskesdas 2013.pdf](http://www.depkes.go.id/resources/download/general/Hasil_Riskesdas_2013.pdf)
3. Zafari A. Myocardial Infarction [Internet]. Medscape. 2015 [cited 2016 Jan 21]. Available from: <http://emedicine.medscape.com/article/155919-overview>
4. Schreiber D. Cardiac Markers [Internet]. Medscape. 2015 [cited 2016 Jan 26]. Available from: <http://emedicine.medscape.com/article/811905-overview>
5. Junpaparp P. Creatine Kinase [Internet]. Medscape. 2014. Available from: <http://emedicine.medscape.com/article/2074023-overview>
6. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation*. 1986;74(5):1124–36.
7. Przyklenk K, Bauer B, Ovize M, Kloner R a, Whittaker P. Regional ischemic “preconditioning” protects remote virgin myocardium from

- subsequent sustained coronary occlusion. *Circulation*. 1993;87:893–9.
8. Birnbaum Y, Hale SL, Kloner RA. Ischemic Preconditioning at a Distance : Reduction of Myocardial Infarct Size by Partial Reduction of Blood Supply Combined With Rapid Stimulation of the Gastrocnemius Muscle in the Rabbit. *Circulation* [Internet]. 1997 Sep 2 [cited 2016 Jan 30];96(5):1641–6. Available from: <http://circ.ahajournals.org/cgi/content/long/96/5/1641>
 9. Addison PD, Neligan PC, Ashrafpour H, Khan A, Zhong A, Moses M, et al. Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction. *Am J Physiol Heart Circ Physiol*. 2003;285(4):H1435–43.
 10. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. *Eur Heart J* [Internet]. 2007;28(20):2525–38. Available from: <http://www.scopus.com/inward/record.url?eid=2-s2.0-35448971466&partnerID=40&md5=6da000f07487c319ac8874491a687419>
 11. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. *Eur Heart J*. 2012;33(20):2551–67.
 12. Lobo Filho HG, Ferreira NL, Sousa RB De, Carvalho ER De, Lobo PLD, Lobo Filho JG. Experimental model of myocardial infarction induced by isoproterenol in rats. *Rev Bras Cir Cardiovasc* [Internet]. 2011;26(3):469–76. Available from: <http://www.gnresearch.org/doi/10.5935/1678-9741.20110024>
 13. Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and




- diastolic dysfunction in mice: Structural and functional correlates. *Comp Med*. 2009;59(4):339–43.
14. S B MR, Kodidhela LD. Origination and Development of Isoproterenol-Induced Myocardial Infarction in Male Wistar Rats. *Int Res J Pharm* [Internet]. 2013;4(5):26–35. Available from:
http://www.irjponline.com/admin/php/uploads/1776_pdf.pdf
 15. Grimm D. Development of heart failure following isoproterenol administration in the rat: role of the renin–angiotensin system. *Cardiovasc Res* [Internet]. 1998;37(1):91–100. Available from:
<http://cardiovascres.oxfordjournals.org/content/37/1/91.long>
 16. Upaganlawar A, Gandhi H, Balaraman R. Isoproterenol Induced Myocardial Infarction: Protective Role of Natural Products [Internet]. *Journal of Pharmacology and Toxicology*. 2011. p. 1–17. Available from:
<http://scialert.net/abstract/?doi=jpt.2011.1.17>
 17. Gassanov N, Nia AM, Caglayan E, Er F. Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option? *J Am Soc Nephrol*. 2014;25(2):216–24.
 18. Veighey K, MacAllister RJ. Clinical applications of remote ischemic preconditioning. *Cardiol Res Pract*. 2012;1(1).
 19. Kloner RA. Clinical application of remote ischemic preconditioning. *Circulation*. 2009;119(6):776–8.
 20. Costa JF, Fontes-Carvalho R, Leite-Moreira AF. Myocardial remote ischemic preconditioning: from pathophysiology to clinical application.

Rev Port Cardiol [Internet]. 2013;32(11):893–904. Available from:
papers3://publication/doi/10.1016/j.repc.2013.02.012

21. Ren C, Gao X, Steinberg GK, Zhao H. Limb remote-preconditioning protects against focal ischemia in rats and contradicts the dogma of therapeutic time windows for preconditioning. *Neuroscience*. 2008;151(4):1099–103.
22. Xu C, Yi C, Guo H, Liu Q, Wang L, Li H. Limb remote ischemic postconditioning is effective but also time-course-limited in protecting the brain from I/R injury. *Turkish J Med Sci*. 2012;42(5):918–29.
23. Chen H, Xu Y, Wang J, Zhao W, Ruan H. Baicalin ameliorates isoproterenol-induced acute myocardial infarction through iNOS , inflammation and oxidative stress in rat. 2015;8(9):10139–47.

LAMPIRAN

Lampiran 1. *Ethical Clearance*

	<p>KOMISI ETIK PENELITIAN KESEHATAN (KEPK) FAKULTAS KEDOKTERAN UNIVERSITAS DIPONEGORO DAN RSUP dr KARIADI SEMARANG Sekretariat : Kantor Dekanat FK Undip Lt.3 Jl. Dr. Soetomo 18. Semarang Telp/Fax. 024-8318350</p>	
<p>ETHICAL CLEARANCE No. 535/EC/FK-RSDK/2016</p>		
<p>Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Diponegoro-RSUP. Dr. Kariadi Semarang, setelah membaca dan menelaah Usulan Penelitian dengan judul :</p>		
<p>"EFEK REMOTE ISCHEMIC PRECONDITIONING TERHADAP KADAR CKMB TIKUS WISTAR PASCA INFARK MIOKARD YANG DIINDUKSI ISOPROTERENOL"</p>		
<p>Peneliti Utama : <i>Muhammad Fa'iz Ramadhan</i></p>		
<p>Pembimbing : -dr. Novi Anggriyani, Sp.JP, FIHA -dr. Noor Wijayahadi, M.Kes, PhD</p>		
<p>Penelitian : Dilaksanakan di Lab. Biologi Fakultas Matematika dan Ilmu Pengetahuan Alam (FMIPA) Universitas Negeri Semarang</p>		
<p>Setuju untuk dilaksanakan, dengan memperhatikan prinsip-prinsip yang dinyatakan dalam Deklarasi Helsinki 1975, yang diamended di Seoul 2008 dan Pedoman Nasional Etik Penelitian Kesehatan (PNEPK) Departemen Kesehatan RI 2011</p>		
<p>Pada laporan akhir peneliti harus melampirkan cara pemeliharaan & dekapitasi hewan coba dan melaporkan ke KEPK bahwa penelitian sudah selesai dilampiri Abstrak Penelitian.</p>		
<p>Semarang, 02 MAY 2016 Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Undip-RS. Dr. Kariadi Ketua, P.K.  Prof. Dr. dr. Suprihati, M.Sc, Sp.THT-KL(K) NIP. 19500621 197703 2 001</p>		

Lampiran 2. Izin Penelitian



KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
 UNIVERSITAS NEGERI SEMARANG
 FAKULTAS MATEMATIKA DAN ILMU PENGETAHUAN ALAM
 LABORATORIUM JURUSAN BIOLOGI
 Gedung D 11 Kampus Sekaran Gunungpati Semarang
 Website : <http://biologi.unnes.ac.id>

Semarang, 29 Maret 2016

Nomor : 371/UN.37.1.4.5/PT/2016
 Lampiran :
 Perihal : Permohonan Ijin Tempat Penelitian


Yth.
 Pembantu Dekan I
 Universitas Diponegoro

Dengan hormat,
 Menjawab Surat saudara No. 2275/UN7.3.4/DI/PP/2016 tanggal 21 Maret 2016 perihal permohonan ijin tempat penelitian dengan menggunakan hewan percobaan, atas nama:

1. Nama : Muhammad Faiz Ramadhan
 NIM : 22010112130085
 2. Nama : Rachmatu Bill Multazam
 NIM : 22010113130177
- Judul : Efek Remote Ischemic Preconditioning terhadap Kadar CKMB dan Luas Kematian Otot Jantung Tikus Wistar Pasca Infark Miokard yang Diinduksi Isoproterenol

Dengan ini kami beritahukan bahwa permohonan ijin tersebut dapat kami setujui sesuai peraturan yang berlaku. Adapun pelaksanaannya akan dibantu oleh teknisi kami sdr. Kartika Widya.

Demikian kami sampaikan, atas perhatian dan kerjasamanya di ucapkan terimakasih

Laboratorium Biologi FMIPA Unnes
 Kepala,

 Dr. Ning Setiati, M.Si.
 NIP. 195903101987032001

Pengelola Kandang Hewan Coba


 drh. Wulan Christijanti, M.Si
 NIP. 196809111996032001

Lampiran 3. Dokumentasi Penelitian



Lampiran 4. Luaran Analisis Program Statistik

Kadar CKMB

Descriptives					
	Kelompok		Statistic	Std. Error	
CKMB	Kontrol	Mean	217,29	17,548	
		95% Confidence Interval for Mean	Lower Bound	174,35	
			Upper Bound	260,22	
		5% Trimmed Mean	216,04		
		Median	215,00		
		Variance	2155,571		
		Std. Deviation	46,428		
		Minimum	152		
		Maximum	305		
		Range	153		
		Interquartile Range	41		
		Skewness	,883	,794	
		Kurtosis	2,429	1,587	
		Perlakuan 1	Mean	224,57	35,922
	95% Confidence Interval for Mean		Lower Bound	136,67	
			Upper Bound	312,47	
	5% Trimmed Mean		223,02		
	Median		199,00		
	Variance		9032,619		
	Std. Deviation		95,040		
	Minimum		117		
	Maximum		360		
	Range		243		
	Interquartile Range		192		
	Skewness		,245	,794	
	Kurtosis		-1,621	1,587	
	Perlakuan 2		Mean	141,14	22,938
		95% Confidence Interval for Mean	Lower Bound	85,01	
			Upper Bound	197,27	
		5% Trimmed Mean	136,94		

		Median	118,00	
		Variance	3683,143	
		Std. Deviation	60,689	
		Minimum	93	
		Maximum	265	
		Range	172	
		Interquartile Range	77	
		Skewness	1,781	,794
		Kurtosis	3,076	1,587

Tests of Normality kadar CKMB

	Kelompok	Shapiro-Wilk		
		Statistic	df	Sig.
Kadar CKMB	Kontrol	,912	7	,410
	Perlakuan 1	,923	7	,496
	Perlakuan 2	,782	7	,027

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality kadar CKMB yang ditransformasi menggunakan fungsi Log 10

	Kelompok	Shapiro-Wilk		
		Statistic	df	Sig.
Transfor masi Log_10	Kontrol	,940	7	,639
	Perlakuan 1	,916	7	,442
	Perlakuan 2	,866	7	,171

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

**Test of Homogeneity of Variances Kadar CKMB
yang ditransformasi**

Levene Statistic	df1	df2	Sig.
2,510	2	18	,109

ANOVA

Kadar CKMB yang ditransformasi

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	,188	2	,094	3,937	,038
Within Groups	,430	18	,024		
Total	,617	20			

Multiple Comparisons

Dependent Variable: Kadar CKMB yang ditransformasi

LSD

(I) Kelompok	(J) Kelompok	Mean Difference (I- J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
Kontrol	Perlakuan 1	,013376231	,082573017	,873	-,16010324	,18685570
	Perlakuan 2	,207021471*	,082573017	,022	,03354200	,38050094
Perlakuan 1	Kontrol	-,013376231	,082573017	,873	-,18685570	,16010324
	Perlakuan 2	,193645240*	,082573017	,031	,02016577	,36712471
Perlakuan 2	Kontrol	-,207021471*	,082573017	,022	-,38050094	-,03354200
	Perlakuan 1	-,193645240*	,082573017	,031	-,36712471	-,02016577

*. The mean difference is significant at the 0.05 level.

Lampiran 5. Biodata Mahasiswa

Identitas

Nama : Muhammad Fa'iz Ramadhan
NIM : 22010112130085
Tempat/Tanggal Lahir : Kebumen, 8 Maret 1994
Jenis Kelamin : Laki-laki
Alamat : Jl. Sersan Suharmaji 05/01 Polaman, Manisrenggo,
Kota Kediri
Nomor HP : 085785776787
Email : mufara99@gmail.com

Riwayat Pendidikan Formal

1. SD : SD N Kras 1, Kabupaten Kediri, lulus tahun 2006
2. SMP : MTs N Kediri 2, Kota Kediri, lulus tahun 2009
3. SMA : SMA N 2 Kediri, Kota Kediri, lulus tahun 2012
4. Perguruan Tinggi : Fakultas Kedokteran UNDIP masuk tahun 2012

Keanggotaan Organisasi

1. MALADICA KU UNDIP dilantik tahun 2014